Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.
Artificial intelligence can detect one of the most common forms of blood cancer - acute myeloid leukemia (AML) - with high reliability.
The progression of cancer has been studied extensively, and the key steps in this journey have been well mapped, at least in some solid tumors: Lesions to genes that confer risk of cancer accumulate and alter normal cell behaviors, giving rise, scientists believe, to early stage cancer cells that eventually swamp normal cells and become deadly.
Parkinson’s disease (PD) is a lifelong condition that affects the nerve cells in the brain that produce dopamine. As a result, people with this neurodegenerative disease experience tremors, changes in speech, gait issues, and muscle rigidity. Though it has no cure, a new drug used to treat cancer shows promise in treating Parkinson’s.
Patients with acute lymphoblastic leukemia or acute myeloid leukemia who are treated with anthracyclines are at a heightened risk of heart failure- most often within one year of exposure to the chemotherapy treatment, according to a new study led by researchers at Penn Medicine.
A clinical trial investigating the repurposed cancer drug nilotinib in people with Parkinson's disease finds that it is reasonably safe and well tolerated.
A collaborative research effort by Australian and US scientists has led to the discovery of a promising new approach to treating some of the worst types of leukaemia, including an aggressive leukaemia that mostly affects babies.
Results from a study conducted by St. Jude Children's Research Hospital and the Munich Leukemia Laboratory were presented today as a late-breaking abstract at the American Society of Hematology annual meeting. The study integrates genomic and transcriptomic sequencing to provide the most detailed classification of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) to date.
In a clinical trial led by Yale Cancer Center and Smilow Cancer Hospital, researchers aim to exploit DNA mutations in the treatment of two blood and bone marrow cancers, a different tacit than the more traditional approach of blunting or switching off genetic mutations linked to cancer.
A bone marrow transplant recipient later found out that the DNA in his blood and semen had been replaced by that of his donor.
Scientists will present more than 40 abstracts highlighting research driven in part by Bio-Rad Laboratories' Droplet Digital PCR (ddPCR) technology at the 2019 American Society of Hematology (ASH) meeting in Orlando Florida, December 7-10.
Deep DNA sequencing analysis conducted by Rutgers Cancer Institute of New Jersey investigators examining genomic differences within tumors for prediction of disease relapse in certain hematologic malignancies has identified small mutations.
A multi-institutional, Phase II study led by The University of Texas MD Anderson Cancer Center showed that pairing standard chemotherapy azacitidine (AZA) with a drug called enasidenib (ENA) measurably boosts complete remission in patients newly diagnosed with a specific form of acute myeloid leukemia (AML).
A new study by Yale Cancer Center researchers shows understanding treatment patterns for patients with acute myeloid leukemia is vital to develop strategies to improve outcomes.
For patients with high-risk myeloid cancers undergoing a donor stem cell transplant, adding the targeted drug venetoclax to a reduced-intensity drug regimen prior to transplant is safe and does not impair the ability of the donor cells to take root in recipients' bodies, a study led by Dana-Farber Cancer Institute researchers suggests.
For older patients with acute myeloid leukemia, the prospects for success of a stem cell transplant can often be predicted based on the particular set of genetic mutations within the tumor cells, investigators at Dana-Farber Cancer Institute and other research centers will report today at the 61st American Society of Hematology (ASH) Annual Meeting.
Cold Spring Harbor Laboratory scientists, with chemists and cancer biologists from Dana-Farber Cancer Institute, have developed a new therapy that extended the survival of mice with acute myeloid leukemia.
Why do some cancers come back? Sometimes, a treatment can effectively eliminate cancer cells to undetectable levels, but, if the treatment stops, cancer may return.
Fujitsu has announced the results of a joint research project it has been conducting with the Institute of Medical Science at the University of Tokyo since April 2018.
Your guacamole may hold the key to managing obesity and helping delay or prevent diabetes, according to a new study by a University of Guelph research team.
A new cancer clinical trial has opened at the M Health Fairview University of Minnesota Medical Center that leverages the groundbreaking research on stem cells and natural killer cells done at the Masonic Cancer Center and applies it to attack acute myeloid leukemia and B-cell lymphoma.